Endometriosis Treatment Market, By Treatment Type, By Drug Class, By Distribution Channel, By Route Of Administration, By Country, and By Region - Global Industry Analysis, Market Size, Market Share & Forecast from 2026-2033

Description

Endometriosis Treatment Market size was valued at US$ 1,971.92 Million in 2025, expanding at a CAGR of 11.32% from 2026 to 2033.

Endometriosis treatment refers to the medical care and supportive remedies that are used to manage an illness in which tissue similar to the lining of the uterus grows outside the uterus. This condition may cause pelvic discomfort, painful menstrual cycles, fatigue, and fertility-related difficulties. These methods are designed to reduce symptoms, improve everyday wellbeing, and support reproductive health goals. Common means include hormone-based medicines, pain-relief therapies, minimally invasive surgeries, and fertility assistance procedures. Doctors usually select treatment plans according to symptom intensity, age, lifestyle needs, and pregnancy considerations, helping patients achieve better long-term health management and improved quality of life.

The treatment is receiving increasing healthcare attention as awareness concerning women's reproductive disorders continues to rise internationally. According to the World Health Organization, around 190 million women and girls of reproductive age are affected by endometriosis worldwide, highlighting the substantial need for diagnosis and care services. The United Kingdom's National Health Service recognizes endometriosis as one of the major causes of chronic pelvic pain and fertility complications among women. In addition, the Australian Government Department of Health has supported national action programs focused on improving early diagnosis, education, and clinical management of endometriosis.

Endometriosis Treatment Market- Market Dynamics

Rising awareness programs and government-backed women's health initiatives to support treatment adoption

Growing understanding towards campaigns and public healthcare schemes is becoming a vital aspect sustaining the development of the endometriosis treatment sector, as more women are diagnosing symptoms earlier and seeking medical direction without delay. Governments in several countries are rising sustenance for education, diagnosis, and specialist care services associated with chronic gynecological syndromes. The Australian Government Department of Health committed more than AUD 127 million under the National Action Plan for Endometriosis to reinforce awareness, clinical management, and research events. In addition, NHS England expanded women's health strategies focused on reducing diagnostic delays and enhancing access to pelvic pain services.

Meanwhile, Health Canada also continues supporting women's reproductive health education and community healthcare measures. On the industry side, Bayer AG continues expanding its women's healthcare portfolio through hormone-related therapy research and gynecology-focused care solutions. Additionally, AbbVie is also firming reproductive health research activities related to chronic inflammatory and hormone-associated conditions.

Endometriosis Treatment Market- Segmentation Analysis:

The Global Endometriosis Treatment Market is segmented on the basis of Treatment Type, Drug Class, Distribution Channel, Route of Administration, and Region.

According to treatment type, market is divided into two classes: hormone therapy and pain medication. The hormone therapy is observed to contribute significantly to the space because it directly targets the hormonal imbalance that influences abnormal tissue growth. This approach is widely preferred in long-term symptom management as it helps in reducing pelvic pain, controlling lesion progression, and improving daily comfort for patients. In clinical development actions, Pfizer Inc. continues to advance research in hormone-related therapies for reproductive health disorders, focusing on improved patient tolerability and treatment outcomes. Also, Gedeon Richter Plc. is expanding its gynecology portfolio with hormone-based treatment solutions aimed at managing endometriosis-related symptoms more effectively.

Under drug class classification, the market is divided into three types: oral contraceptives, NSAIDs, and gonadotropin-releasing hormone. Gonadotropin Releasing Hormone therapy is expected to remain highly influential in endometriosis management due to its ability to regulate hormone levels and reduce estrogen-driven tissue growth, which is a major cause of symptoms. It is often used in patients with moderate to severe conditions when initial pain relief options are not sufficient. This method is gradually maintained by pharmaceutical innovation directed at improving safety profiles and patient comfort in long-term use. Takeda Pharmaceutical Company is actively involved in developing advanced therapies in gynecology and hormone-related disorders, strengthening its reproductive health pipeline. Similarly, Novartis AG continues to invest in research programs targeting hormone regulation and chronic inflammatory conditions.

Endometriosis Treatment Market- Geographical Insights

In terms of regional distribution, the market determines its growth outlines across regions due to variances in healthcare awareness, diagnostic access, and women's health support systems. North America exhibits a prominent involvement in this market due to solid healthcare organizations, higher awareness about women's reproductive illnesses, and continuous support for advanced gynecological studies. The region benefits from early diagnosis programs, access to minimally invasive surgical procedures, and wider availability of hormone-based and fertility-related therapies through hospitals and specialty clinics. According to the World Health Organization, endometriosis affects nearly 190 million women and girls of reproductive age globally, highlighting the growing need for structured treatment systems and awareness initiatives.

The National Institutes of Health (NIH) says that endometriosis affects around 5% to 10% of women in the United States, supporting continuous investment in diagnostic and therapeutic research. Moreover, the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) recognizes endometriosis as one of the most common gynecological disorders associated with pain and infertility, encouraging long-term clinical studies and treatment innovation. From a commercial view, AbbVie continued to focus on women's healthcare research activities related to hormone therapies, while Pfizer Inc. expanded its focus on inflammatory and reproductive health treatment innovation.

Germany Endometriosis Treatment Market- Country Insights

In terms of healthcare development, Germany implements a structured and research-focused method toward endometriosis management, as it is maintained by strong hospital systems and national-level clinical direction. According to the Federal Ministry of Health of Germany, government-backed initiatives have recently assigned around €10 million to support women's health research, with endometriosis emphasized as a priority area for better diagnosis and treatment pathways. The Robert Koch Institute also highlights chronic disease observation and supports national health data collection, helping enhance understanding of gynecological conditions across populations.

In addition, the German Federal Statistical Office reports rising hospital-based treatment cases for endometriosis over recent years, signaling improved detection and medical attention. On the clinical side, Bayer AG continues to contribute to reproductive health innovation through hormone-based therapy research and women's healthcare solutions. These efforts display a healthcare system where government research funding, national health monitoring, and pharmaceutical innovation work in a direction to improve early diagnosis, patient care access, and long-term treatment support for endometriosis patients across Germany.

Endometriosis Treatment Market- Competitive Landscape:

The Endometriosis Treatment market is developing slowly as pharmaceutical companies, healthcare providers, and biotechnology firms work toward improving women's health solutions via advanced therapies and supportive care options. Industries are concentrating on hormone-based medicines, non-hormonal drug expansion, minimally invasive surgical support, and fertility-related treatment services to address long-standing unmet medical needs. Treatment access is growing through specialty clinics, hospital networks, retail pharmacies, and digital healthcare channels. Major participants shaping this space include AbbVie, Bayer AG, Pfizer Inc., Gedeon Richter Plc., and ObsEva SA, which continue to strengthen treatment accessibility and reproductive health research programs globally.

Industry applicants are progressively highlighting patient-focused therapies, long-term symptom management, and partnerships supporting innovation in gynecological care. Many organizations are also investing in clinical studies, digital monitoring tools, and precision medicine approaches to improve diagnosis and treatment outcomes. For example, NHS England approved the rollout of a daily oral relugolix combination therapy designed to support easier home-based endometriosis management. Meanwhile, Maipl Therapeutics cooperated with Endosure Inc. to sustain clinical development of non-hormonal treatment solutions, indicating rising interest in less invasive and more personalized care methods across women's healthcare services.

Recent Developments:

In March 2026, EndoCyclic Therapeutics received U.S. FDA clearance to begin human clinical trials for ENDO-205, a non-hormonal investigational therapy aimed at targeting endometriosis lesions directly. The development reflects growing industry interest in precision-based and non-surgical treatment alternatives in women's healthcare.

In September 2025, Gesynta Pharma received approval from UK health authorities to initiate a Phase II clinical study for vipoglanstat in patients with endometriosis. The study is intended to evaluate the safety and effectiveness of the investigational therapy across several European clinical sites.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL ENDOMETRIOSIS TREATMENT MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

AbbVie Inc.
AstraZeneca
Bayer AG
Pfizer Inc.
Sanofi
Teva Pharmaceutical Industries Ltd.
Zydus Lifesciences Ltd.
Astellas Pharma Inc.
Gesynta Pharma
Gedeon Richter Plc.
Takeda Pharmaceutical Company Limited
Kissei Pharmaceutical Co., Ltd.
Merck & Co., Inc.
Eli Lilly and Company
Johnson & Johnson
Ferring Pharmaceuticals
EndoCyclic Therapeutics
Myovant Sciences
Ipsen Pharma
Abbott Laboratories
Sun Pharmaceutical Industries Ltd.
Neurocrine Biosciences Inc.
Evotec SE
Others

GLOBAL ENDOMETRIOSIS TREATMENT MARKET, BY TREATMENT TYPE- MARKET ANALYSIS, 2020 - 2033

Hormone Therapy
Pain Medication
Others

GLOBAL ENDOMETRIOSIS TREATMENT MARKET, BY DRUG CLASS- MARKET ANALYSIS, 2020 - 2033

Oral Contraceptive
NSAIDs
Gonadotropin Releasing Hormone
Others

GLOBAL ENDOMETRIOSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL- MARKET ANALYSIS, 2020 - 2033

Retail Pharmacy
Hospital Pharmacy
Others

GLOBAL ENDOMETRIOSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION- MARKET ANALYSIS, 2020 - 2033

Injectable
Oral
Others

GLOBAL ENDOMETRIOSIS TREATMENT MARKET, BY REGION- MARKET ANALYSIS, 2020 - 2033

North America
U.S.
Canada
Europe
Germany
UK
France
Italy
Spain
The Netherlands
Sweden
Russia
Poland
Denmark
Rest of Europe
Asia Pacific
China
India
Japan
South Korea
Australia
Indonesia
Thailand
Philippines
Taiwan
Vietnam
Rest of APAC
Latin America
Brazil
Mexico
Argentina
Colombia
Rest of LATAM
The Middle East and Africa
Saudi Arabia
UAE
Israel
Turkey
Algeria
Egypt
Iran
Qatar
Rest of MEA

Product Code: ANV6529

1. Endometriosis Treatment Market Overview

1.1. Study Scope
1.2. Market Estimation Years

2. Executive Summary

2.1. Market Snippet
- 2.1.1. Endometriosis Treatment Market Snippet by Treatment Type
- 2.1.2. Endometriosis Treatment Market Snippet by Drug Class
- 2.1.3. Endometriosis Treatment Market Snippet by Distribution Channel
- 2.1.4. Endometriosis Treatment Market Snippet by Route Of Administration
- 2.1.5. Endometriosis Treatment Market Snippet by Country
- 2.1.6. Endometriosis Treatment Market Snippet by Region
2.2. Competitive Insights

3. Endometriosis Treatment Key Market Trends

3.1. Endometriosis Treatment Market Drivers
- 3.1.1. Impact Analysis of Market Drivers
3.2. Endometriosis Treatment Market Restraints
- 3.2.1. Impact Analysis of Market Restraints
3.3. Endometriosis Treatment Market Opportunities
3.4. Endometriosis Treatment Market Future Trends

4. Endometriosis Treatment Industry Study

4.1. PEST Analysis
4.2. Porter's Five Forces Analysis
4.3. Growth Prospect Mapping
4.4. Regulatory Framework Analysis

5. Endometriosis Treatment Market: Impact of Escalating Geopolitical Tensions

5.1. Impact of COVID-19 Pandemic
5.2. Impact of Russia-Ukraine War
5.3. Impact of Middle East Conflicts

6. Endometriosis Treatment Market Landscape

6.1. Endometriosis Treatment Market Share Analysis, 2025
6.2. Breakdown Data, by Key Manufacturer
- 6.2.1. Established Players' Analysis
- 6.2.2. Emerging Players' Analysis

7. Endometriosis Treatment Market - By Treatment Type

7.1. Overview
- 7.1.1. Segment Share Analysis, By Treatment Type, 2025 & 2033 (%)
- 7.1.2. Hormone Therapy
- 7.1.3. Pain Medication
- 7.1.4. Others

8. Endometriosis Treatment Market - By Drug Class

8.1. Overview
- 8.1.1. Segment Share Analysis, By Drug Class, 2025 & 2033 (%)
- 8.1.2. Oral Contraceptive
- 8.1.3. NSAIDs
- 8.1.4. Gonadotropin Releasing Hormone
- 8.1.5. Others

9. Endometriosis Treatment Market - By Distribution Channel

9.1. Overview
- 9.1.1. Segment Share Analysis, By Distribution Channel, 2025 & 2033 (%)
- 9.1.2. Retail Pharmacy
- 9.1.3. Hospital Pharmacy
- 9.1.4. Others

10. Endometriosis Treatment Market - By Route Of Administration

10.1. Overview
- 10.1.1. Segment Share Analysis, By Route Of Administration, 2025 & 2033 (%)
- 10.1.2. Injectable
- 10.1.3. Oral
- 10.1.4. Others

11. Endometriosis Treatment Market- By Geography

11.1. Introduction
- 11.1.1. Segment Share Analysis, By Geography, 2025 & 2033 (%)
11.2. North America
- 11.2.1. Overview
- 11.2.2. Endometriosis Treatment Key Manufacturers in North America
- 11.2.3. North America Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
- 11.2.4. North America Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
- 11.2.5. North America Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
- 11.2.6. North America Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
- 11.2.7. North America Market Size and Forecast, By Route Of Administration, 2020 - 2033 (US$ Million)
- 11.2.8. U.S.
  - 11.2.8.1. Overview
  - 11.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 11.2.8.3. U.S. Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
  - 11.2.8.4. U.S. Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
  - 11.2.8.5. U.S. Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
  - 11.2.8.6. U.S. Market Size and Forecast, By Route Of Administration, 2020 - 2033 (US$ Million)
- 11.2.9. Canada
  - 11.2.9.1. Overview
  - 11.2.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 11.2.9.3. Canada Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
  - 11.2.9.4. Canada Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
  - 11.2.9.5. Canada Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
  - 11.2.9.6. Canada Market Size and Forecast, By Route Of Administration, 2020 - 2033 (US$ Million)
11.3. Europe
- 11.3.1. Overview
- 11.3.2. Endometriosis Treatment Key Manufacturers in Europe
- 11.3.3. Europe Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
- 11.3.4. Europe Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
- 11.3.5. Europe Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
- 11.3.6. Europe Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
- 11.3.7. Europe Market Size and Forecast, By Route Of Administration, 2020 - 2033 (US$ Million)
- 11.3.8. Germany
  - 11.3.8.1. Overview
  - 11.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 11.3.8.3. Germany Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
  - 11.3.8.4. Germany Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
  - 11.3.8.5. Germany Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
  - 11.3.8.6. Germany Market Size and Forecast, By Route Of Administration, 2020 - 2033 (US$ Million)
- 11.3.9. UK
  - 11.3.9.1. Overview
  - 11.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 11.3.9.3. UK Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
  - 11.3.9.4. UK Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
  - 11.3.9.5. UK Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
  - 11.3.9.6. UK Market Size and Forecast, By Route Of Administration, 2020 - 2033 (US$ Million)
- 11.3.10. France
  - 11.3.10.1. Overview
  - 11.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 11.3.10.3. France Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
  - 11.3.10.4. France Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
  - 11.3.10.5. France Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
  - 11.3.10.6. France Market Size and Forecast, By Route Of Administration, 2020 - 2033 (US$ Million)
- 11.3.11. Italy
  - 11.3.11.1. Overview
  - 11.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 11.3.11.3. Italy Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
  - 11.3.11.4. Italy Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
  - 11.3.11.5. Italy Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
  - 11.3.11.6. Italy Market Size and Forecast, By Route Of Administration, 2020 - 2033 (US$ Million)
- 11.3.12. Spain
  - 11.3.12.1. Overview
  - 11.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 11.3.12.3. Spain Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
  - 11.3.12.4. Spain Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
  - 11.3.12.5. Spain Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
  - 11.3.12.6. Spain Market Size and Forecast, By Route Of Administration, 2020 - 2033 (US$ Million)
- 11.3.13. The Netherlands
  - 11.3.13.1. Overview
  - 11.3.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 11.3.13.3. The Netherlands Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
  - 11.3.13.4. The Netherlands Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
  - 11.3.13.5. The Netherlands Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
  - 11.3.13.6. The Netherlands Market Size and Forecast, By Route Of Administration, 2020 - 2033 (US$ Million)
- 11.3.14. Sweden
  - 11.3.14.1. Overview
  - 11.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 11.3.14.3. Sweden Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
  - 11.3.14.4. Sweden Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
  - 11.3.14.5. Sweden Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
  - 11.3.14.6. Sweden Market Size and Forecast, By Route Of Administration, 2020 - 2033 (US$ Million)
- 11.3.15. Russia
  - 11.3.15.1. Overview
  - 11.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 11.3.15.3. Russia Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
  - 11.3.15.4. Russia Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
  - 11.3.15.5. Russia Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
  - 11.3.15.6. Russia Market Size and Forecast, By Route Of Administration, 2020 - 2033 (US$ Million)
- 11.3.16. Poland
  - 11.3.16.1. Overview
  - 11.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 11.3.16.3. Poland Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
  - 11.3.16.4. Poland Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
  - 11.3.16.5. Poland Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
  - 11.3.16.6. Poland Market Size and Forecast, By Route Of Administration, 2020 - 2033 (US$ Million)
- 11.3.17. Denmark
  - 11.3.17.1. Overview
  - 11.3.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 11.3.17.3. Poland Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
  - 11.3.17.4. Denmark Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
  - 11.3.17.5. Denmark Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
  - 11.3.17.6. Denmark Market Size and Forecast, By Route Of Administration, 2020 - 2033 (US$ Million)
- 11.3.18. Rest of Europe
  - 11.3.18.1. Overview
  - 11.3.18.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 11.3.18.3. Rest of the Europe Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
  - 11.3.18.4. Rest of the Europe Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
  - 11.3.18.5. Rest of the Europe Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
  - 11.3.18.6. Rest of the Europe Market Size and Forecast, By Route Of Administration, 2020 - 2033 (US$ Million)
11.4. Asia Pacific (APAC)
- 11.4.1. Overview
- 11.4.2. Endometriosis Treatment Key Manufacturers in Asia Pacific
- 11.4.3. APAC Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
- 11.4.4. APAC Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
- 11.4.5. APAC Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
- 11.4.6. APAC Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
- 11.4.7. APAC Market Size and Forecast, By Route Of Administration, 2020 - 2033 (US$ Million)
- 11.4.8. China
  - 11.4.8.1. Overview
  - 11.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 11.4.8.3. China Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
  - 11.4.8.4. China Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
  - 11.4.8.5. China Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
  - 11.4.8.6. China Market Size and Forecast, By Route Of Administration, 2020 - 2033 (US$ Million)
- 11.4.9. India
  - 11.4.9.1. Overview
  - 11.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 11.4.9.3. India Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
  - 11.4.9.4. India Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
  - 11.4.9.5. India Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
  - 11.4.9.6. India Market Size and Forecast, By Route Of Administration, 2020 - 2033 (US$ Million)
- 11.4.10. Japan
  - 11.4.10.1. Overview
  - 11.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 11.4.10.3. Japan Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
  - 11.4.10.4. Japan Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
  - 11.4.10.5. Japan Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
  - 11.4.10.6. Japan Market Size and Forecast, By Route Of Administration, 2020 - 2033 (US$ Million)
- 11.4.11. South Korea
  - 11.4.11.1. Overview
  - 11.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 11.4.11.3. South Korea Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
  - 11.4.11.4. South Korea Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
  - 11.4.11.5. South Korea Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
  - 11.4.11.6. South Korea Market Size and Forecast, By Route Of Administration, 2020 - 2033 (US$ Million)
- 11.4.12. Australia
  - 11.4.12.1. Overview
  - 11.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 11.4.12.3. Australia Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
  - 11.4.12.4. Australia Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
  - 11.4.12.5. Australia Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
  - 11.4.12.6. Australia Market Size and Forecast, By Route Of Administration, 2020 - 2033 (US$ Million)
- 11.4.13. Indonesia
  - 11.4.13.1. Overview
  - 11.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 11.4.13.3. Indonesia Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
  - 11.4.13.4. Indonesia Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
  - 11.4.13.5. Indonesia Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
  - 11.4.13.6. Indonesia Market Size and Forecast, By Route Of Administration, 2020 - 2033 (US$ Million)
- 11.4.14. Thailand
  - 11.4.14.1. Overview
  - 11.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 11.4.14.3. Thailand Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
  - 11.4.14.4. Thailand Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
  - 11.4.14.5. Thailand Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
  - 11.4.14.6. Thailand Market Size and Forecast, By Route Of Administration, 2020 - 2033 (US$ Million)
- 11.4.15. Philippines
  - 11.4.15.1. Overview
  - 11.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 11.4.15.3. Philippines Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
  - 11.4.15.4. Philippines Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
  - 11.4.15.5. Philippines Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
  - 11.4.15.6. Philippines Market Size and Forecast, By Route Of Administration, 2020 - 2033 (US$ Million)
- 11.4.16. Taiwan
  - 11.4.16.1. Overview
  - 11.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 11.4.16.3. Taiwan Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
  - 11.4.16.4. Taiwan Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
  - 11.4.16.5. Taiwan Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
  - 11.4.16.6. Taiwan Market Size and Forecast, By Route Of Administration, 2020 - 2033 (US$ Million)
- 11.4.17. Vietnam
  - 11.4.17.1. Overview
  - 11.4.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 11.4.17.3. Vietnam Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
  - 11.4.17.4. Vietnam Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
  - 11.4.17.5. Vietnam Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
  - 11.4.17.6. Vietnam Market Size and Forecast, By Route Of Administration, 2020 - 2033 (US$ Million)
- 11.4.18. Rest of APAC
  - 11.4.18.1. Overview
  - 11.4.18.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 11.4.18.3. Rest of APAC Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
  - 11.4.18.4. Rest of APAC Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
  - 11.4.18.5. Rest of APAC Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
  - 11.4.18.6. Rest of APAC Market Size and Forecast, By Route Of Administration, 2020 - 2033 (US$ Million)
11.5. Latin America (LATAM)
- 11.5.1. Overview
- 11.5.2. Endometriosis Treatment Key Manufacturers in Latin America
- 11.5.3. LATAM Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
- 11.5.4. LATAM Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
- 11.5.5. LATAM Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
- 11.5.6. LATAM Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
- 11.5.7. LATAM Market Size and Forecast, By Route Of Administration, 2020 - 2033 (US$ Million)
- 11.5.8. Brazil
  - 11.5.8.1. Overview
  - 11.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 11.5.8.3. Brazil Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
  - 11.5.8.4. Brazil Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
  - 11.5.8.5. Brazil Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
  - 11.5.8.6. Brazil Market Size and Forecast, By Route Of Administration, 2020 - 2033 (US$ Million)
- 11.5.9. Mexico
  - 11.5.9.1. Overview
  - 11.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 11.5.9.3. Mexico Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
  - 11.5.9.4. Mexico Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
  - 11.5.9.5. Mexico Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
  - 11.5.9.6. Mexico Market Size and Forecast, By Route Of Administration, 2020 - 2033 (US$ Million)
- 11.5.10. Argentina
  - 11.5.10.1. Overview
  - 11.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 11.5.10.3. Argentina Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
  - 11.5.10.4. Argentina Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
  - 11.5.10.5. Argentina Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
  - 11.5.10.6. Argentina Market Size and Forecast, By Route Of Administration, 2020 - 2033 (US$ Million)
- 11.5.11. Colombia
  - 11.5.11.1. Overview
  - 11.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 11.5.11.3. Colombia Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
  - 11.5.11.4. Colombia Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
  - 11.5.11.5. Colombia Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
  - 11.5.11.6. Colombia Market Size and Forecast, By Route Of Administration, 2020 - 2033 (US$ Million)
- 11.5.12. Rest of LATAM
  - 11.5.12.1. Overview
  - 11.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 11.5.12.3. Rest of LATAM Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
  - 11.5.12.4. Rest of LATAM Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
  - 11.5.12.5. Rest of LATAM Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
  - 11.5.12.6. Rest of LATAM Market Size and Forecast, By Route Of Administration, 2020 - 2033 (US$ Million)
11.6. Middle East and Africa (MEA)
- 11.6.1. Overview
- 11.6.2. Endometriosis Treatment Key Manufacturers in Middle East and Africa
- 11.6.3. MEA Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
- 11.6.4. MEA Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
- 11.6.5. MEA Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
- 11.6.6. MEA Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
- 11.6.7. MEA Market Size and Forecast, By Route Of Administration, 2020 - 2033 (US$ Million)
- 11.6.8. Saudi Arabia
  - 11.6.8.1. Overview
  - 11.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 11.6.8.3. Saudi Arabia Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
  - 11.6.8.4. Saudi Arabia Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
  - 11.6.8.5. Saudi Arabia Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
  - 11.6.8.6. Saudi Arabia Market Size and Forecast, By Route Of Administration, 2020 - 2033 (US$ Million)
- 11.6.9. United Arab Emirates
  - 11.6.9.1. Overview
  - 11.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 11.6.9.3. United Arab Emirates Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
  - 11.6.9.4. United Arab Emirates Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
  - 11.6.9.5. United Arab Emirates Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
  - 11.6.9.6. United Arab Emirates Market Size and Forecast, By Route Of Administration, 2020 - 2033 (US$ Million)
- 11.6.10. Israel
  - 11.6.10.1. Overview
  - 11.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 11.6.10.3. Israel Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
  - 11.6.10.4. Israel Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
  - 11.6.10.5. Israel Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
  - 11.6.10.6. Israel Market Size and Forecast, By Route Of Administration, 2020 - 2033 (US$ Million)
- 11.6.11. Turkey
  - 11.6.11.1. Overview
  - 11.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 11.6.11.3. Turkey Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
  - 11.6.11.4. Turkey Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
  - 11.6.11.5. Turkey Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
  - 11.6.11.6. Turkey Market Size and Forecast, By Route Of Administration, 2020 - 2033 (US$ Million)
- 11.6.12. Algeria
  - 11.6.12.1. Overview
  - 11.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 11.6.12.3. Algeria Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
  - 11.6.12.4. Algeria Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
  - 11.6.12.5. Algeria Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
  - 11.6.12.6. Algeria Market Size and Forecast, By Route Of Administration, 2020 - 2033 (US$ Million)
- 11.6.13. Egypt
  - 11.6.13.1. Overview
  - 11.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 11.6.13.3. Egypt Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
  - 11.6.13.4. Egypt Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
  - 11.6.13.5. Egypt Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
  - 11.6.13.6. Egypt Market Size and Forecast, By Route Of Administration, 2020 - 2033 (US$ Million)
- 11.6.14. Iran
  - 11.6.14.1. Overview
  - 11.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 11.6.14.3. Iran Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
  - 11.6.14.4. Iran Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
  - 11.6.14.5. Iran Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
  - 11.6.14.6. Iran Market Size and Forecast, By Route Of Administration, 2020 - 2033 (US$ Million)
- 11.6.15. Qatar
  - 11.6.15.1. Overview
  - 11.6.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 11.6.15.3. Qatar Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
  - 11.6.15.4. Qatar Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
  - 11.6.15.5. Qatar Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
  - 11.6.15.6. Qatar Market Size and Forecast, By Route Of Administration, 2020 - 2033 (US$ Million)
- 11.6.16. Rest of MEA
  - 11.6.16.1. Overview
  - 11.6.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 11.6.16.3. Rest of MEA Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
  - 11.6.16.4. Rest of MEA Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
  - 11.6.16.5. Rest of MEA Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
  - 11.6.16.6. Rest of MEA Market Size and Forecast, By Route Of Administration, 2020 - 2033 (US$ Million)

12. Key Vendor Analysis- Endometriosis Treatment Industry

12.1. Competitive Benchmarking
- 12.1.1. Competitive Dashboard
- 12.1.2. Competitive Positioning
12.2. Company Profiles
- 12.2.1. AbbVie Inc.
- 12.2.2. AstraZeneca
- 12.2.3. Bayer AG
- 12.2.4. Pfizer Inc.
- 12.2.5. Sanofi
- 12.2.6. Teva Pharmaceutical Industries Ltd.
- 12.2.7. Zydus Lifesciences Ltd.
- 12.2.8. Astellas Pharma Inc.
- 12.2.9. Gesynta Pharma
- 12.2.10. Gedeon Richter Plc.
- 12.2.11. Takeda Pharmaceutical Company Limited
- 12.2.12. Kissei Pharmaceutical Co., Ltd.
- 12.2.13. Merck & Co., Inc.
- 12.2.14. Eli Lilly and Company
- 12.2.15. Johnson & Johnson
- 12.2.16. Ferring Pharmaceuticals
- 12.2.17. EndoCyclic Therapeutics
- 12.2.18. Myovant Sciences
- 12.2.19. Ipsen Pharma
- 12.2.20. Abbott Laboratories
- 12.2.21. Sun Pharmaceutical Industries Ltd.
- 12.2.22. Neurocrine Biosciences Inc.
- 12.2.23. Evotec SE
- 12.2.24. Others

13. 360 Degree AnalystView

14. Appendix

14.1. Research Methodology
14.2. References
14.3. Abbreviations
14.4. Disclaimer
14.5. Contact Us